Apollon Formularies Plc Result of General Meeting

 
TIDMAPOL 
 
11 April 2023 
 
                            Apollon Formularies Plc 
 
                                 Result of GM 
 
Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a UK-based 
international medical cannabis pharmaceutical company specialising in cutting 
edge research and treatment of patients with various conditions including 
cancer, chronic pain and epilepsy, is pleased to announce that following the 
Company's General Meeting held  on 11 April 2023, all resolutions were duly 
passed. 
 
As announced on 21 March 2023, the 28-day due diligence period extended to 
Global Hemp Group is expected to conclude on 28 April 2023. A further 
announcement will be made in due course. 
 
The Asset disposal circular remains available at https://apollon.org.uk/. 
 
The Directors of the Company accept responsibility for the contents of this 
announcement. 
 
                                    -ENDS- 
 
For additional information, please visit www.apollon.org.uk or contact: 
 
Apollon Formularies 
 
Tel:                                                      +44 771 198 0221 
 
Stene Jacobs                                      stene@apollon.org.uk 
 
Peterhouse Capital Limited (Corporate Adviser) 
 
Tel:                                                       +44 207 220 9795 
 
Guy Miller                                           gm@peterhousecapital.com 
 
BlytheRay (Financial PR/IR-London) 
 
Tel:                                                       +44 207 138 3204 
 
Tim Blythe/Megan Ray                    apollon@blytheray.com 
 
About Apollon Formularies and Apollon Formularies Jamaica 
 
Apollon Formularies plc is an international medical cannabis and medicinal 
mushroom pharmaceutical company headquartered in the United Kingdom. Apollon 
Formularies Jamaica Limited is a pharmaceutical company incorporated and 
operating in the Commonwealth of Jamaica since 2016. Apollon Jamaica is 
licensed by the Jamaican government's Cannabis Licensing Authority (CLA) to 
cultivate, perform research and development, process, and sell therapeutic 
products that include legal medical cannabis to treat various illnesses under 
medical supervision. 
 
Apollon's proprietary medical cannabis formulations have undergone third-party 
testing which demonstrated the successful killing of nearly 100% of prostate, 
triple negative and HER2+ breast cancer cells in 3D cell cultures. Apollon's 
products are also used to treat patients suffering from different conditions, 
including chronic pain and epilepsy. 
 
 
 
END

(END) Dow Jones Newswires

April 11, 2023 09:00 ET (13:00 GMT)

Apollon Formularies (AQSE:APOL)
Historical Stock Chart
From Mar 2024 to Apr 2024